TOX as a potential target for immunotherapy in lymphocytic malignancies-Reference-Cited by-同舟云学术

TOX as a potential target for immunotherapy in lymphocytic malignancies

Published:2021-03-20 Issue:1 Volume:9 Page:
ISSN:2050-7771
Container-title:Biomarker Research
language:en
Short-container-title:Biomark Res

Author:

Liang Chaofeng,Huang Shuxin,Zhao Yujie,Chen Shaohua^ORCID,Li Yangqiu^ORCID

Abstract

AbstractTOX (thymocyte selection-associated HMG BOX) is a member of a family of transcriptional factors that contain the highly conserved high mobility group box (HMG-box) region. Increasing studies have shown that TOX is involved in maintaining tumors and promoting T cell exhaustion. In this review, we summarized the biological functions of TOX and its contribution as related to lymphocytic malignancies. We also discussed the potential role of TOX as an immune biomarker and target in immunotherapy for hematological malignancies.

Funder

National Natural Science Foundation of China

Guangzhou Science, Technology and Innovation Commission

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry, medical,Clinical Biochemistry,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40364-021-00275-y.pdf

Reference53 articles.

1. Sekine T, Perez-Potti A, Nguyen S, Gorin JB, Wu VH, Gostick E, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci Immunol. 2020;5(49):eaba7918.

2. Cheng Y, Shao Z, Chen L, Zheng Q, Zhang Q, Ding W, Zhang M, Yu Q, Gao D, et al. Role, function and regulation of the thymocyte selection-associated high mobility group box protein in CD8(+) T cell exhaustion. Immunol Lett. 2021;229:1–7. https://doi.org/10.1016/j.imlet.2020.11.004.